- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06001281
Predictive Value of Soluble CD146 in Glioblastoma Patients (MUCIGLIO-01)
Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent and fails to enhance patients' overall survival. The investigators previously identified one novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022).
Now, the investigators objective is to prospectively monitor the soluble CD146 value in plasma from patients treated by bevacizumab for recurrent glioblastoma.
The investigators will collect plasma at baseline, before the first bevacizumab administration, before the second administration, at the time of first MRI evaluation and at progression. Plasma CD146 value will be analyzed by ELISA.
The investigators expect to confirm the correlation between soluble CD146 value in plasma and patient response to bevacizumab.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: DRSMR AP-HM
- Email: promotion.interne@ap-hm.fr
Study Contact Backup
- Name: Emeline Tabouret
- Phone Number: 33 0491385500
- Email: emeline.tabouret@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Recruiting
- Service de Neuro-oncologie
-
Contact:
- TABOURET Emeline
- Phone Number: 33 0491385500
- Email: emeline.tabouret@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - Adult patients with recurrent IDHwt glioblastoma
- Relapse after standard first line treatment (radio-chemotherapy)
- Candidate for bevacizumab treatment
- Able to be monitored by MRI
- KPS ≥ 60%
- Written signed consent form
Exclusion Criteria:
- Pregnancy or breast feeding
- Life expectancy less than 3 months
- Bevacizumab in first line treatment
- Other concomitant life-threatening disease
- Under legal protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: plasma collection
Plasma samples will be prospectively collected at relevant time points during patient treatment.
|
Plasma samples will be prospectively collected at relevant time points during patient treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
correlation between soluble CD146 plasma value and patient response (RANO)
Time Frame: first evaluation (2 months)
|
Soluble CD146 plasma value will be assessed using ELISA.
Patient response will be evaluated by MRI and clinical response using the international RANO criteria.
|
first evaluation (2 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emeline Tabouret, AP-HM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCAPHM23_0011
- Id RCB (Registry Identifier: 2018-A00771-54)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on plasma collection
-
University of FloridaNational Institutes of Health (NIH); DiaCarta, Inc.Completed
-
Haemonetics CorporationCompletedApheresis Related HypotensionUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Gdansk University of Physical Education and SportCompletedCoronary DiseasePoland
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingMetastatic Clear Cell Renal CarcinomaItaly
-
Hôpital Européen MarseilleRecruiting
-
Centre Hospitalier Universitaire de Pointe-a-PitreDirection Générale de l'Offre de SoinsRecruitingDyslipidemia | Sickle Cell Disease | ComplicationFrance
-
Hôpital Européen MarseilleRecruiting
-
OncoHost Ltd.RecruitingStage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant MelanomaUnited States, Israel, United Kingdom, Germany, Spain